Search results for
5187 items
Equality and Human Rights Consultation - NICE TA - Roflumilast for Treating Chronic Obstructive Pulmonary Disease
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Collagenase Clostridium Histolyticum for Treating Dupuytren’s Contracture
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Trastuzumab Emtansine for Treating HER2 Positive Advanced Breast Cancer after Trastuzumab and a Taxane (Review of TA371)
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Pirfenidone for treating Idiopathic Pulmonary Fibrosis (Review of TA282)
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Adalimumab, Etanercept and Ustekinumab for Treating Severe, Chronic Plaque Psoriasis in Children and Young People
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Adalimumab and Dexamethasone for Treating Non-Infectious Uveitis
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Etelcalcetide for treating secondary hyperparathyroidism
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Everolimus, Lutetium-177 DOTATATE and Sunitinib for Treating Unresectable or Metastatic Neuroendocrine Tumours with Disease Progression
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Blinatumomab for treating Philadelphia-chromosome-negative relapsed or refractory acute lymphoblastic leukaemia
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Ponatinib for Treating Chronic Myeloid Leukaemia and Acute Lymphoblastic Leukaemia
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Brentuximab Vedotin for Treating CD30-Positive Hodgkin’s Lymphoma
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Certolizumab Pegol and Secukinumab for Treating Active Psoriatic Arthritis Following Inadequate Response to Disease Modifying Anti-Rheumatic Drugs
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer after Gemcitabine
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Daclizumab for Treating Relapsing-Remitting Multiple Sclerosis
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Ixekizumab for Treating Moderate to Severe Plaque Psoriasis
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Cetuximab and Panitumumab for Previously Untreated Metastatic Colorectal Cancer (Review of TA176 & Part Review of TA240)
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Obeticholic Acid for Treating Primary Biliary Cholangitis
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Everolimus for the Second-Line Treatment of Metastatic Renal Cell Carcinoma (Review of TA219)
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the
Equality and Human Rights Consultation - NICE TA - Apremilast for Treating Active Psoriatic Arthritis (Rapid Review TA372)
NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the